This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Global Anticoagulants Industry

9. PRODUCT INTRODUCTIONS/APPROVALS IN RECENT PAST- A PERSPECTIVE

BUILDER II-60

GSK Receives EU Approval for Arixtra® II-60

Pradaxa Receives FDA Approval II-60

Canyon Pharmaceuticals Introduces Iprivask II-60

Teva Receives FDA's Tentative Approval for Argatroban II-60

TrimGen Receives FDA 510(k) Approval for Marketing eQ-PCR™ LC

Warfarin Genotyping Kit II-61

Lundbeck Launches ATryn® Commercially in the US II-61

The Medicines Co Receives European Approval for Angiox (

Bivalirudin) II-61

 

10. RECENT INDUSTRY ACTIVITY II-62

FDA Issues Complete Response Letter for Eliquis's New Drug

Application II-62

FDA Issues Complete Response Letter to Rivaroxaban's (Xarelto)

NDA for ACS II-62

US FDA Extends Date for Eliquis' New Drug Application II-62

Pradaxa® Receives NICE Recommendation II-62

BioInvent and ThromboGenics Discontinue Development of TB-402 II-62

Watson Receives Stay Order on Preliminary Injunction II-63

FDA Assigns Priority Review for Xarelto Supplemental NDA II-63

Portola Pharmaceuticals Re-Acquires Rights to Betrixaban II-63

FDA Accepts New Drug Application for ELIQUIS® II-63

Astellas Pharma Halts Development of Anticoagulant II-63

Sanofi-Aventis Changes Name to Sanofi II-63

 

11. CORPORATE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER II-64

Boehringer Ingelheim Expands Manufacturing Capacity at Ingelheim II-64

Sagent Pharmaceuticals Secures FDA Approval for Heparin Sodium

Injection II-64

Biomet Acquires Cytosol Laboratories II-64

Portola Inks $470 M Agreement with Merck for Phase II

Anticoagulant II-64

Catalent Pharma Inks Strategic Alliance Deal with Endotis Pharma II-65

Nuvelo and ARCA biopharma Merge II-65

 

12. FOCUS ON SELECT GLOBAL PLAYERS II-66

Bayer Healthcare AG ( Germany) II-66

Boehringer Ingelheim ( Germany) II-66

Bristol-Myers Squibb Company ( USA) II-66

Eisai Inc. ( USA) II-67

GlaxoSmithKline plc (UK) II-67

LEO Pharmaceutical Products ( Denmark) II-67

Mitsubishi Tanabe Pharma Corporation ( Japan) II-68

Pfizer Inc. ( USA) II-68

Sanofi ( France) II-68

Teva Pharmaceutical Industries Ltd ( Israel) II-69

Teva Pharmaceuticals USA ( USA) II-69

 

5 of 15

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs